Back to top
more

MacroGenics (MGNX)

(Delayed Data from NSDQ)

$3.83 USD

3.83
1,407,793

-0.17 (-4.25%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $3.82 -0.01 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

by Zacks Equity Research

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.

Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?

by Zacks Equity Research

LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.

Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?

by Zacks Equity Research

We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.

Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?

by Zacks Equity Research

On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.

Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?

by Zacks Equity Research

Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.

Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?

by Zacks Equity Research

IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.

MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

by Zacks Equity Research

MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.

Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.

Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?

by Zacks Equity Research

Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.

What Lies Ahead for Abbott (ABT) Stock This Earnings Season?

by Zacks Equity Research

Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.

4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

by Zacks Equity Research

Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.

Nabaparna Bhattacharya headshot

Medical Products Industry Gathering Steam: 3 Stocks to Buy

by Nabaparna Bhattacharya

The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.

The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas

Nabaparna Bhattacharya headshot

5 Beaten-Down Medical Product Stocks to Rebound in 2019

by Nabaparna Bhattacharya

As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

What's in Store for GW Pharma (GWPH) This Earnings Season?

by Zacks Equity Research

On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 37.21% and 236.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

MacroGenics has been struggling lately, but the selling pressure may be coming to an end soon.

    MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MacroGenics (MGNX) delivered earnings and revenue surprises of 14.17% and 327.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      What's in Store for Penumbra (PEN) This Earnings Season?

      by Zacks Equity Research

      Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.

        4 Medical Product Stocks Likely to Top Q3 Earnings Estimates

        by Zacks Equity Research

        The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.